Sheikh Shakhbout Medical City and AstraZeneca launch an asthma inhaler recycling initiative
ABU DHABI (ALETIHAD)Sheikh Shakhbout Medical City (SSMC), a flagship hospital in the UAE for severe and complex care and a subsidiary of the PureHealth group, has today announced its collaboration with global biopharmaceutical company AstraZeneca to launch the 'Pure Air Solution' (PAS) initiative.This partnership, formalised through a Memorandum of Understanding (MoU), focuses on the recycling of asthma inhalers. While demonstrating a shared commitment to sustainable healthcare practices, this initiative also addresses the urgent need to reduce the healthcare sector's carbon footprint, which currently contributes to approximately 5% of the world's greenhouse gas (GHG) emissions. Commenting on the launch of the initiative, Dr. Marwan Al Kaabi, chief executive officer at SSMC, said: 'By implementing a comprehensive inhaler recycling programme, SSMC and AstraZeneca are taking a significant step towards mitigating environmental harm, which aligns with the UAE's vision for net-zero carbon emissions by 2050.'Through the strategic placement of collection bins across SSMC's key clinics and pharmacies, the initiative will encourage asthma patients to participate in inhaler recycling. The partnership will also prioritise robust educational campaigns on asthma management and the importance of recycling, empowering both patients and staff at SSMC to engage in responsible disposal practices.Dr. Al Kaabi added, 'The PAS initiative is further testament to SSMC's leadership in proactive environmental stewardship within the healthcare sector. By launching this programme, we are taking decisive strides towards a healthier, more sustainable future, while setting a precedent and establishing a benchmark for responsible healthcare practices within the region.'Sameh El Fangary, cluster president for GCC and Pakistan at AstraZeneca, shared: 'Partnering with SSMC reflects our shared commitment to advancing innovative and sustainable respiratory care. This collaboration aims to reduce the environmental impact associated with inhaler use, aligning with our integrated approach to health, addressing both patient outcomes and environmental considerations.'Project leads Dr. Haytham Shahata, research clinical pharmacist, and Dr. Lubna Issa, drug store operations manager at SSMC, said: 'Inhalers, among the most prevalent medical devices used in the UAE, account for nearly 80% of inhaler-related GHG output.1 This is largely attributable to hydrofluorocarbon propellants, which are up to 2,500 times more potent than carbon dioxide and can remain in the atmosphere for over 200 years.2,3 With 96% of an inhaler's climate impact stemming from these potent emissions, the PAS initiative is designed to significantly minimise the carbon footprint of respiratory care.4'
The PAS initiative reinforces the power of collaborative innovation in building a sustainable healthcare ecosystem. By fostering a culture of recycling and education, SSMC and AstraZeneca are taking the lead in advancing sustainable healthcare practices across the UAE, ultimately benefiting patients and the broader community by ensuring long-term health and environmental well-being.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
10 hours ago
- Al Etihad
UAEU research reveals new insights into cellular regulation pathways
8 July 2025 19:26 AL AIN (ALETIHAD)A research team from the United Arab Emirates University (UAEU) has made a significant breakthrough in understanding how cells positively regulate their study offers new insight into the complex mechanisms that enable cells to adapt and respond to changing environmental research was conducted under the supervision of Dr. Mohammad Tauqeer Alam, associate professor in the Department of Biology, College of Science, in collaboration with Prof. Markus Ralser from Charité – Universitätsmedizin Berlin, Germany, and Dr. Richard Notebaart from Wageningen University and Research, Netherlands. The study was published in the journal Molecular Systems student Sultana Mohammed Al Zubaidi and PhD student Muhammad Ibtisam Nasar were the first co-authors of the Alam explained that the research provided a comprehensive network of intracellular enzyme–metabolite activator interactions by integrating the yeast metabolic network with enzyme data from multiple species. The findings revealed that most metabolic pathways include activatory interactions often linking across different pathways, highlighting extensive regulatory crosstalk within the cell's metabolic key discovery is that the early steps in many metabolic pathways are positively regulated, effectively priming downstream reactions for more efficient execution. This enhances overall metabolic study also found that the most highly catalytic enzymes are often involved in secondary pathways, which are activated under specific environmental conditions. Meanwhile, macromolecules play an essential role in cell survival. Dr. Alam emphasised that these findings represent a major step forward in understanding how cells regulate internal processes. The insights open new avenues for research in metabolic engineering, biotechnology, and disease biology. Source: Aletihad - Abu Dhabi
Al Etihad
15 hours ago
- Al Etihad
Emirates Drug Establishment approves world's first oral therapy for immune thrombocytopenia
8 July 2025 14:37 ABU DHABI (WAM) The Emirates Drug Establishment (EDE) has granted official approval for Rilzabrutinib, the first oral Bruton's tyrosine kinase (BTK) inhibitor to be authorised in the country for the treatment of Immune Thrombocytopenia (ITP), a rare autoimmune disorder that affects approximately 2 to 5 individuals per 100,000 people this landmark approval, the UAE becomes the first country in the world to authorise this innovative medication, reflecting the nation's global leadership in accelerating access to advanced treatments and addressing critical medical approval of Rilzabrutinib in the UAE represents a major step forward, offering patients with ITP early access to a pioneering therapeutic solution that contributes to a faster treatment journey and a tangible improvement in quality of decision aligns with the UAE's strategic commitment to ensuring the availability of high-efficacy, globally benchmarked treatments in line with the highest international standards and by global pharmaceutical and healthcare company Sanofi, Rilzabrutinib represents a breakthrough in restoring immune system balance by targeting the underlying cause of increasing platelet counts, the treatment addresses both the symptoms and root causes of the condition. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, stated, 'The UAE is committed to providing access to the world's latest therapeutic innovations and further promoting its position as a regional hub for pharmaceutical excellence. With Rilzabrutinib getting approved, we take another step further in achieving our strategy aimed at enhancing national pharmaceutical security, implementing advanced treatment protocols, and streamlining regulatory frameworks in collaboration with international partners.'Dr. Al Kaabi emphasised that the milestone demonstrates the effectiveness of the UAE's proactive healthcare policies and flexible regulatory systems in fostering innovation and facilitating patient access to advanced medications.'The Emirates Drug Establishment will spare no effort to accelerate regulatory procedures, and strengthen global partnerships,' she said. 'This further solidifies the UAE's role as a regional centre for pharmaceutical innovation.'She added, 'Granting approval for Rilzabrutinib reaffirms the Establishment's commitment to fast-tracking access to transformative therapies that create significant impact, particularly in the treatment of rare and chronic diseases. EDE will continue to adopt a proactive, innovation-driven approach, fuelled by international collaboration, to ensure that safe, effective therapeutic options are available across the country in accordance with the highest global standards. Our goal is to enhance the UAE's health system preparedness in an era of rapid scientific progress.' For her part, Preeti Futnani, MCO Lead and General Manager, Specialty Care for KSA & Gulf Countries at Sanofi, said, 'We are honoured to collaborate with the Emirates Drug Establishment to bring this groundbreaking treatment to patients in the UAE living with Immune Thrombocytopenia. The approval of Rilzabrutinib demonstrates our shared commitment to placing patients at the centre of our mission and delivering cutting-edge solutions that address some of the most pressing unmet medical needs.'
Al Etihad
17 hours ago
- Al Etihad
Abu Dhabi leads high-level delegation to US, showcasing emirate's global leadership in healthcare innovation
8 July 2025 13:10 ABU DHABI (ALETIHAD)Department of Health – Abu Dhabi (DoH) has led a high-level delegation on a strategic mission to the US to strengthen partnerships and showcase Abu Dhabi's excellence in life sciences and precision visit reflected the emirate's global leadership in healthcare innovation and its commitment to international cooperation to advance scientific research, innovation, and ethical medical delegation visited key US cities including Boston, Washington DC, and Philadelphia, in parallel with Abu Dhabi's participation at BIO International Convention 2025, one of the world's foremost biotechnology visit spotlighted the emirate's achievements in AI, digital health, genomics, and clinical research, and showcased Abu Dhabi's Health, Endurance, Longevity and Medicine (HELM) Life Science Cluster, while promoting long-term strategic partnerships with government entities, research institutions, and global Excellency Dr Noura Khamis Al Ghaithi, Undersecretary of DoH, said: 'This mission demonstrated Abu Dhabi's ongoing efforts to cement its position as a global centre of excellence in health and life sciences. We are committed to fostering partnerships that advance healthcare innovation and enhance quality of life, both in the UAE and globally.'The delegation conducted more than 20 strategic meetings and visits with public and private sector leaders across the US, aimed at enhancing knowledge exchange and investment opportunities, and marked the signing of new agreements that will accelerate the adoption of advanced health mission facilitated joint actions between DoH and global organisations set to shape the future of healthcare. These alliances reinforce the Emirate's steadfast dedication to advancing health outcomes through impactful global collaborations, pioneering research and a robust infrastructure that fosters innovation, talent and investment. Key agreements and partnerships were formed with prestigious US-based peers and partners, including the University of California, San Francisco, the Innovative Genomics Institute, Sanofi, Boehringer Ingelheim, Abbott, Aetna International, GEMMABio and Children's National Hospital. These collaborations focus on establishing genome surgery centres, advancing vaccine development and manufacturing, integrating innovative research platforms and localising pharmaceutical production, while also expanding access to US healthcare networks, developing genomics and biotechnology research centres and launching advanced cell and gene therapy programmes for the side-lines of Abu Dhabi's participation at BIO International Convention in Boston, USA, the Department of Health – Abu Dhabi, in collaboration with Johnson & Johnson (J&J) and Sheikh Shakhbout Medical City (SSMC), a flagship hospital in the UAE for serious and complex care and a subsidiary of the PureHealth group, have successfully enabled expedited access to Tremfya®, a next-generation biologic medication for patients with Inflammatory Bowel Disease (IBD). This strategic partnership marks the first availability of the treatment outside the United States, reinforcing Abu Dhabi's position as a as a pioneering destination for healthcare innovation and advanced, patient-focused Abu Dhabi's innovation ecosystem, the delegation included key stakeholders such as Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD Group, PureHealth, StartAD, Khalifa University, New York University Abu Dhabi, and Etihad Dhabi continues to lead the region in genomics through the Emirati Genome Programme, which has successfully sequenced more than 800,000 samples, creating one of the most advanced national genomic databases. The emirate is also home to more than 90 licensed research centres and over 30 ongoing clinical trials in areas such as oncology, rare diseases, and chronic data platforms such as Malaffi, which securely store over 5 million patient records—enable AI-powered insights and real-world evidence, while national initiatives like the Golden Visa have enabled more than 2,000 long-term visas for researchers and healthcare professionals from around the world. This strategic visit reflected Abu Dhabi's broader vision for healthcare transformation—driven by innovation, investment, and a deep commitment to global collaboration.
